The association between ABO blood groups and TASC II classification in patients with peripheral artery disease

Multiple Logistic Regression Analysis ◽

Blood Groups ◽

Abo Blood Groups ◽

Peripheral Artery ◽

Entire Study ◽

Study Results ◽

Study Population ◽

Objective The aim of this study was to investigate the association between blood groups and severity of peripheral artery disease (PAD) using TASC II classification. Methods The patients who were diagnosed with PAD were retrospectively analyzed. The patients with 50% or more stenosis in the aorto-iliac or femoro-popliteal region detected by conventional or CT angiography were included in the study. These patients were divided into TASC II A, B, C, and D groups considering the severity of PAD. All patients’ blood groups were recorded and compared between TASC II groups. Results While 38% of the study population was O blood group, 61% were non-O group. On the other hand, 90% of the entire study population were RH positive and 10% were RH negative. Non-O blood ratio was found to be significantly higher in patients with higher TASC II groups. (TASC IIA 51.6% vs. TASC IIB 57.9% vs. TASC IIC 61.3% vs. TASC IID 76.6%, p< .001) However, the frequencies of Rh types were similar in all groups. Multiple logistic regression analysis was applied for determining the predictors of severity and complexity of PAD (TASC II C and TASC II D lesions) Conclusions Our study results revealed a clear association between ABO blood groups and severity of peripheral arterial disease. Non-O blood group was found to be the independent predictor of severe and complex PAD.

Association of ABO blood group with CAD in patients undergoing CAG in Cardiology Department of Dhaka Medical College and Hospital

University Heart Journal ◽

10.3329/uhj.v10i2.26126 ◽

2015 ◽

Vol 10 (2) ◽

pp. 81-84 ◽

Cited By ~ 1

Author(s):

Md Nazmul Hasan ◽

Abdul Wadud Chowdhury ◽

Lahani Md Tajul Islam ◽

Mohammad Safiuddin ◽

Mostashirul Haque ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Blood Group ◽

Blood Groups ◽

Abo Blood Group ◽

Medical College ◽

Cardiology Department ◽

Study Population ◽

Artery Disease ◽

Group B

There are many reports regarding association between ABO and Rhesus blood groups and coronary artery disease. This study has been designed to see the association of ABO blood group with coronary artery disease in patient who were admitted in Cardiology Department of Dhaka Medical College and Hospital and undergoing coronary angiography. A total of 680 patients were studied in this retrospective study. ABO blood group, gender and standard cardiovascular risk factors were determined. In our study 17.5% of the study population were female with mean age of 49.94±10.37 years and 82.5% were male with a mean age 49.68±10.45 years . Most of the patients belonged to blood group B (33.4%) .Our results demonstrated the prevalence of CAD in blood group B is much higher than other blood groups which is in contrast with other studies in few other countries including one study done on small groups of people in Bangladesh. Geographical distribution may explain the variation in results among countries.University Heart Journal Vol. 10, No. 2, July 2014; 81-84

Association between ABO blood groups and susceptibility to COVID-19: profile of age and gender in Iraqi patients

Egyptian Journal of Medical Human Genetics ◽

10.1186/s43042-020-00115-y ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Ali H. Ad’hiah ◽

Maha H. Abdullah ◽

Mustafa Y. Alsudani ◽

Rasool M. S. Shnawa ◽

Ali J. R. Al-Sa’ady ◽

...

Keyword(s):

Blood Group ◽

Group Analysis ◽

Blood Groups ◽

Control Group ◽

Age Group ◽

Abo Blood Groups ◽

Characteristic Analysis ◽

Increased Risk ◽

Study Results ◽

Group A

Abstract Background A case-control study was performed to examine age, gender, and ABO blood groups in 1014 Iraqi hospitalized cases with Coronavirus disease 2019 (COVID-19) and 901 blood donors (control group). The infection was molecularly diagnosed by detecting coronavirus RNA in nasal swabs of patients. Results Mean age was significantly elevated in cases compared to controls (48.2 ± 13.8 vs. 29.9 ± 9.0 year; probability [p] < 0.001). Receiver operating characteristic analysis demonstrated the predictive significance of age in COVID-19 evolution (Area under curve = 0.858; 95% CI: 0.841 – 0.875; p < 0.001). Males outnumbered females in cases (60.4 vs. 39.6%) and controls (56 vs. 44%). Stratification by age group (< 30, 30 – 39, 40 – 49 and ≥ 50 years) revealed that 48.3% of cases clustered in the age group ≥ 50 years. ABO blood group analysis showed that group A was the most common among cases, while group O was the most common among controls (35.5 and 36.7%, respectively). Blood groups A (35.5 vs. 32.7; corrected p [pc] = 0.021), A+AB (46.3 vs. 41.7%; pc = 0.021) and A+B+AB (68.0 vs. 63.3%; pc = 0.007) showed significantly elevated frequencies in cases compared to controls. Logistic regression analysis estimated odds ratios (ORs) of 1.53 (95% confidence interval [CI]: 1.16 - 2.02), 1.48 (95% CI: 1.14 - 1.93) and 1.50 (95% CI: 1.17 - 1.82) for blood groups A, A+AB and A+B+AB, respectively. Blood group frequencies showed no significant differences between age groups of cases or controls. Regarding gender, male cases were marked with increased frequency of group A (39.9 vs. 28.9%) and decreased frequency of group O (25.9 vs. 41.0%) compared to female cases. Independent re-analysis of ABO blood groups in male and female cases demonstrated that group A was increased in male cases compared to male controls (39.9 vs. 33.1%; OR = 1.65; 95% CI: 1.24 - 2.21; pc = 0.006). On the contrary, no significant differences were found between females of cases and controls. Conclusions The study results indicated that blood group A may be associated with an increased risk of developing COVID-19, particularly in males.

Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus

Journal of Endovascular Therapy ◽

10.1177/1526602817705135 ◽

2017 ◽

Vol 24 (3) ◽

pp. 376-382 ◽

Cited By ~ 20

Author(s):

Andrew N. Shammas ◽

Haekyung Jeon-Slaughter ◽

Shirling Tsai ◽

Houman Khalili ◽

Mujtaba Ali ◽

...

Keyword(s):

Diabetes Mellitus ◽

Lower Extremity ◽

Endovascular Procedures ◽

Major Amputation ◽

Peripheral Artery ◽

Entire Study ◽

Endovascular Revascularization ◽

Increased Risk ◽

Purpose: To determine whether diabetes mellitus has an independent impact on major limb outcomes at 1 year after endovascular treatment of lower extremity peripheral artery disease (PAD). Methods: The study involved 1906 consecutive patients (mean age 66 years; 1469 men) enrolled in the observational Excellence in Peripheral Artery Disease (XLPAD) registry ( ClinicalTrials.gov identifier NCT01904851) between January 2005 and October 2015 after undergoing index endovascular procedures in 2426 limbs for arterial occlusive disease. Patient outcomes included 12-month target limb amputation (above ankle) and target limb revascularization as well as all-cause death. Kaplan-Meier analysis and adjusted Cox proportional hazard models were used for time-to-event analysis of outcomes for the entire study sample as well as for the critical limb ischemia (CLI) and claudication subgroups. Results of the Cox regression models are reported as the hazard ratio (HR) and 95% confidence interval (CI). Results: Diabetics undergoing endovascular procedures had higher rates of comorbid conditions (p<0.001), CLI (p<0.001), heavily calcified lesions (p=0.002), multivessel disease (p=0.030), and fewer infrapopliteal runoff vessels (p<0.001). Regression analysis after adjusting for confounders revealed significantly higher target limb major amputation in diabetics compared with nondiabetics (HR 5.02, 95% CI 1.44 to 17.56, p=0.011). However, repeat revascularization rates were similar. When considering CLI and claudication subgroups, diabetes was associated with a nonsignificant increased risk of 12-month major amputation only for patients presenting with CLI (HR 3.48, 95% CI 0.97 to 12.51, p=0.056). Diabetes was also associated with an increased risk of 12-month all-cause mortality in the overall study sample (HR 4.64, 95% CI 2.01 to 10.70, p<0.001) and in the CLI subgroup (HR 14.15, 95% CI 3.16 to 63.32, p<0.001) but not in the claudication subgroup (HR 1.42, 95% CI 0.45 to 4.54, p=0.552). Conclusion: Diabetes increases the risk of major amputation and all-cause death at 12 months following endovascular revascularization in patients with symptomatic PAD. These risks are especially heightened in patients presenting with CLI.

German guideline on the diagnosis and treatment of peripheral artery disease – a comprehensive update 2016

VASA ◽

10.1024/0301-1526/a000603 ◽

2017 ◽

Vol 46 (2) ◽

pp. 79-86 ◽

Cited By ~ 26

Author(s):

Holger Lawall ◽

Peter Huppert ◽

Christine Espinola-Klein ◽

Claudia Silke Zemmrich ◽

Gerhard Ruemenapf

Keyword(s):

Surgical Techniques ◽

Diagnosis And Treatment ◽

Critical Limb Ischaemia ◽

Diagnostic Tools ◽

Limb Ischaemia ◽

Peripheral Artery ◽

Medical Societies ◽

Study Results ◽

Abstract. The prevalence of peripheral artery disease (PAD) is increasing worldwide and is strongly age-related, affecting about 20 % of Germans over 70 years of age. Recent advances in endovascular and surgical techniques as well as clinical study results on comparative treatment methods strengthened the need for a comprehensive review of the published evidence for diagnosis, management, and prevention of PAD. The interdisciplinary guideline exclusively covers distal aorta and atherosclerotic lower extremity artery disease. A systematic literature review and formal consensus finding process, including delegated members of 22 medical societies and two patient self-support organisations were conducted and supervised by the Association of Scientific Medical Societies in Germany, AWMF. Three levels of recommendation were defined, A = „is recommended/indicated”, B = „should be considered”, C = “may be considered”, means agreement of expert opinions due to lack of evidence. Altogether 294 articles, including 34 systematic reviews and 98 RCTs have been analysed. The key diagnostic tools and treatment basics have been defined. In patients with intermittent claudication endovascular and/or surgical techniques are treatment options depending on appropriate individual morphology and patient preference. In critical limb ischaemia, revascularisation without delay by means of the most appropriate technique is key. If possible and reasonable, endovascular procedures should be applied first. The TASC classification is no longer recommended as the base of therapeutic decision process due to advances in endovascular techniques and new crural therapeutic options. Limited new data on rehabilitation and follow-up therapies have been integrated. The article summarises major new aspects of PAD treatment from the updated German Guidelines for Diagnosis and Treatment of PAD. Limited scientific evidence still calls for randomised clinical trials to close the present gap of evidence.

Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease

BMJ Open ◽

10.1136/bmjopen-2021-049858 ◽

2021 ◽

Vol 11 (9) ◽

pp. e049858

Author(s):

Kristen J Bubb ◽

Jason A Harmer ◽

Meghan Finemore ◽

Sarah Joy Aitken ◽

Zara S Ali ◽

...

Keyword(s):

Intermittent Claudication ◽

Adrenergic Receptors ◽

Step Count ◽

Life Assessment ◽

Walking Distance ◽

Controlled Study ◽

Peripheral Artery ◽

Study Results ◽

IntroductionThere is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β3-adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with peripheral artery disease. The aim of the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial is to test whether mirabegron improves walking distance in people with intermittent claudication.Methods and analysisThe STAR-PAD trial is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD. A total of 120 patients aged ≥40 years with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either mirabegron (50 mg orally once a day) or matched placebo, for 12 weeks. The primary endpoint is change in peak walking distance as assessed by a graded treadmill test. Secondary endpoints will include: (i) initial claudication distance; (ii) average daily step count and total step count and (iii) functional status and quality of life assessment. Mechanistic substudies will examine potential effects of mirabegron on vascular function, including brachial artery flow-mediate dilatation; MRI assessment of lower limb blood flow, tissue perfusion and arterial stiffness and numbers and angiogenesis potential of endothelial progenitor cells. Given that mirabegron is safe and clinically available for alternative purposes, a positive study is positioned to immediately impact patient care.Ethics and disseminationThe STAR-PAD trial is approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/18/HAWKE/50). The study results will be published in peer-reviewed medical or scientific journals and presented at scientific meetings, regardless of the study outcomes.Trial registration numberACTRN12619000423112; Results.

Infections and ABO Blood Groups in Burn Patients.

Blood ◽

10.1182/blood.v106.11.4179.4179 ◽

2005 ◽

Vol 106 (11) ◽

pp. 4179-4179

Author(s):

Areta Kowal-Vern ◽

Leonard I. Boral ◽

Mariano G. Yogore ◽

Harita Patel ◽

Susan Brown

Keyword(s):

Blood Group ◽

Inhalation Injury ◽

Blood Groups ◽

Burn Patients ◽

Abo Blood Groups ◽

Chi Square ◽

Significant Difference ◽

Study Population ◽

Tract Infections ◽

Burn Patient

Abstract Background: Lack of isohemmaglutinins may predispose individuals to infection. The purpose of this study was to determine if there was a relationship between infections and burn patient blood groups. Methods: This was a retrospective review of burn patient data on infections and ABO blood groups between March 1999-May 2004. Chi-square and Mann-Whitney U with one-way ANOVA statistical analyses were performed. Results: There were 1615 burn admissions; 794 patients were typed for blood groups; 179 patients received blood transfusions. Of the study population, African-Americans constituted 59%, Hispanics 21%, Caucasians 16%, and others 4%. Although age (mean±se: 37±2 years), % TBSA (11±2%), and inhalation injury (15%) were similar in all groups, patients with B blood group had longer BICU stays compared to the O blood group, p<0.01. There was no statistically significant difference among the blood groups in the number of nosocomial wound infections, episodes of sepsis, bacteremia, urinary tract infections (UTIs) or pneumonia. The bacterial etiology was similar in all blood groups without any species preponderance. Transfused patients had a higher frequency of infections compared to those who were not transfused and significance was only reached in the comparison for UTIs, p=0.02. Conclusions: Our data shows that burn patients with B and AB blood groups did not have an increased frequency of infections compared to the patients with A and O blood groups. Burn patients were immunosuppressed as part of their injury. Those who received transfusions probably had a further perturbation of their immune system, since blood products cause immunosuppression. Other factors such as inhalation injury and %TBSA also predisposed burn patients to infection. Transfusions rather than blood groups were associated with an increased number of nosocomial UTIs in burn patients. Demographic Characteristics of the Burn Population by ABO Groups Blood Groups AB A B O mean ± s.e. Study Population # (%) 27 (3) 258 (32) 134 (17) 375 (47) Study African American (%) 4 29 21 46 Study Hispanic (%) 1 36 7 56 Study Caucasian (%) 3 37 14 46 BICU stay (days) 15±6 13±2 23±4 11±1 PRBC Transfusions (units) 7±2 9±2 13±3 8±1 UTI/Transfused # (%) 5 (100) 12 (92) 8 (89) 20 (60) UTI/Not Transfused # (%) 0 1 (8) 1 (11) 13 (40)

Associations of coronary and peripheral artery disease with presence, expansion, and rupture of abdominal aortic aneurysm – a grin without a cat!

VASA ◽

10.1024/0301-1526/a000606 ◽

2017 ◽

Vol 46 (3) ◽

pp. 151-158 ◽

Cited By ~ 4

Author(s):

Hisato Takagi ◽

Takuya Umemoto

Keyword(s):

Abdominal Aortic Aneurysm ◽

Aortic Aneurysm ◽

Literature Search ◽

Systematic Literature Search ◽

Peripheral Artery ◽

Epidemiological Evidence ◽

Abdominal Aortic ◽

Artery Disease ◽

Meta Analyses

Abstract. Both coronary and peripheral artery disease are representative atherosclerotic diseases, which are also known to be positively associated with presence of abdominal aortic aneurysm. It is still controversial, however, whether coronary and peripheral artery disease are positively associated with expansion and rupture as well as presence of abdominal aortic aneurysm. In the present article, we overviewed epidemiological evidence, i. e. meta-analyses, regarding the associations of coronary and peripheral artery disease with presence, expansion, and rupture of abdominal aortic aneurysm through a systematic literature search. Our exhaustive search identified seven meta-analyses, which suggest that both coronary and peripheral artery disease are positively associated with presence of abdominal aortic aneurysm, may be negatively associated with expansion of abdominal aortic aneurysm, and might be unassociated with rupture of abdominal aortic aneurysm.